The University of Chicago Header Logo

Connection

Seenu Hariprasad to Integrins

Back to Details
This is a "connection" page, showing publications Seenu Hariprasad has written about Integrins.
Seenu Hariprasad
Connection Strength
0.173
Integrins
  1. Risuteganib-a novel integrin inhibitor for the treatment of non-exudative (dry) age-related macular degeneration and diabetic macular edema. Expert Opin Investig Drugs. 2020 Jun; 29(6):547-554.
    View in: PubMed
    Score: 0.173
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.